Bayer challenges Nexavar generic license order in India

Sat May 5, 2012 9:43pm IST

Board members of Bayer AG attend the annual general meeting in Cologne April 27, 2012. REUTERS/Ina Fassbender

Board members of Bayer AG attend the annual general meeting in Cologne April 27, 2012.

Credit: Reuters/Ina Fassbender

Related Topics

Stocks

   

(Reuters) - Drugmaker Bayer said on Saturday it had challenged an Indian patents office order that allowed domestic rival Natco Pharma to sell a cheap generic version of the German firm's liver and kidney cancer drug Nexavar in India.

In March, the patents office stripped Bayer of its exclusive rights to sell Nexavar, saying most Indians could not afford it.

It told Natco Pharma to sell the generic drug significantly more cheaply and pay Bayer a 6 percent royalty on sales.

Bayer said it had appealed against the ruling. "We will rigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients," a company spokesman said.

India's decision on Nexavar was seen as a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms.

Separately, Bayer is suing another Indian drugmaker, Cipla, (CIPL.NS) for patent infringement over Nexavar. Cipla has been selling generic Nexavar in India and it has slashed the price of the drug by 75 percent to 6,840 Indian rupees a month.

(Reporting by Kaustubh Kulkarni in Mumbai; Editing by Alistair Lyon)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Scotland Referendum

Scotland Referendum

Scots vote in record numbers, await independence verdict.  Full Article 

India-US Diplomacy

India-US Diplomacy

Obama to nominate Indian-American Richard Verma as India ambassador - congressional source.  Full Article 

GMR in Nepal

GMR in Nepal

Nepal clears India’s GMR plan for $1.4 bln hydroelectric plant.  Full Article 

LIC on Markets

LIC on Markets

LIC chairman bullish on Indian markets  Full Article 

India Rains

India Rains

Monsoon rains weaken as late retreat looms.  Full Article 

Ellison Quits

Ellison Quits

Oracle's Ellison steps aside, co-CEOs Catz and Hurd take over.  Full Article 

Infosys-Huawei

Infosys-Huawei

Infosys partners with China's Huawei for cloud-based services  Full Article 

Gold Outlook

Gold Outlook

Gold imports seen up, premiums likely to double on festive buying  Full Article 

Trade Dispute

Trade Dispute

U.S. to press India on trade row during Modi's Washington visit  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage